NM Fundus On Phone (NMFOP)

The patented optical design (US patent # 9398851) and simplicity of a smartphone enables the user to capture reflex free high quality images of the retina at the click of a button.

DOWNLOAD BROCHURE

SIMPLE TO USE

BATTERY POWERED

NON-MYDRATIC

AI READY*

Screen Anyone, Anywhere,
Anytime.

Remidio Fundus On Phone is the world’s first and the only smartphone based, Infrared enabled, high quality disease detection and triaging device to enable universal screening for eye health.

AI Ready*

Artificial intelligence can play a unique role in public health screening for detection of Diabetic Retinopathy. Remidio has clinically validated two different AI algorithms : EyeArt from EyeNuk, CA, USA and Medios Technologies from Singapore.

* EyeArt from EyeNuk has been cleared for sales as a Class II a medical device by EU and as a Class 2 medical device by Health Canada. In the US, EyeArt is limited by federal law to investigational use and is not available for sale.

Medios AI is cleared as a Class II Medical Device in the EU and is available for investigational use only in the US.

Experience the Clarity ! Choose a Clinical Condition



Captured on NM-FOP

HOVER THE IMAGE TO EXPAND

Multiple Mounting Modes

The Fundus on Phone is extremely compact by design, with the width of the system measuring just 6.8cm and weight over 1.5kg. The design allows it to be used even in the most space-starved settings! It can be used in mass screening programs such as screening for Cataract, Glaucoma and Diabetic Retinopathy.

HANDHELD

SLIT LAMP MOUNTABLE

TABLE-MOUNTED

Designed for Telemedicine

FOP is an ideal platform for comprehensive telemedicine enabled eye-wellness screening. The cloud synchronized mobile application of FOPNM-10 enables images to be synced and archived securely in the cloud for remote review and clinical management. Remidio Web Application allows the user to securely login and review images remotely across the globe.

Intuitive APP

Remidio Fundus-NM IOS application is,

  • -Simple to use
  • -HIPAA Complaint
  • -Cloud enabled
  • -DICOM compliant#
  • # DICOM App not available for sale in the US

Validations and Publications

Remidio FOP is shown to have a clinical specificity of 98% for any DR against Zeiss FF450.

 

Remidio FOP Vs Zeiss FF450

Retinopathy

Sensitivity

Specificity

Any DR92.798.4
DME89.898.4
PDR89.195.8
STDR86.694.6
RDR87.994.9
  
 

EyeArt Vs Ophthamologist

Retinopathy

Sensitivity

Specificity

Any DR95.880.2
DME97.075.2
PDR78.189.8
STDR99.180.4
RDR99.168.8
  

Published in Nature Eye.

 

Medios AI Vs Ophthalmologist

Retinopathy

Sensitivity

Specificity

Any DR85.292
RDR10088.4
  

Under review for publication in JAMA Ophthalmology.